JP2002516283A - 核転写因子ＮＦ−κＢの活性化の阻害剤としての２−ヒドロキシ−４−トリフルオロメチル安息香酸誘導体の使用 - Google Patents

核転写因子ＮＦ−κＢの活性化の阻害剤としての２−ヒドロキシ−４−トリフルオロメチル安息香酸誘導体の使用

Info

Publication number
JP2002516283A
JP2002516283A JP2000550490A JP2000550490A JP2002516283A JP 2002516283 A JP2002516283 A JP 2002516283A JP 2000550490 A JP2000550490 A JP 2000550490A JP 2000550490 A JP2000550490 A JP 2000550490A JP 2002516283 A JP2002516283 A JP 2002516283A
Authority
JP
Japan
Prior art keywords
prodrug
pharmaceutically acceptable
formula
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000550490A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002516283A5 (https=
Inventor
マニュエル、マーロス、ロカ
アルベルト、フェルナンデス、デ、アリーバ
フェルナンド、カバルカンティ、デ、マリア
アグスティ、ミラレス、アコスタ
マリアーノ、サンチェス、クレスポ
ジュリアン、ガルシア、ラファネル
ハビエル、フォーン、ダルマウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noucor Health SA
Original Assignee
J Uriach y Cia SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J Uriach y Cia SA filed Critical J Uriach y Cia SA
Publication of JP2002516283A publication Critical patent/JP2002516283A/ja
Publication of JP2002516283A5 publication Critical patent/JP2002516283A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2000550490A 1998-05-27 1999-05-26 核転写因子ＮＦ−κＢの活性化の阻害剤としての２−ヒドロキシ−４−トリフルオロメチル安息香酸誘導体の使用 Pending JP2002516283A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES9801154 1998-05-27
ES009801154A ES2136581B1 (es) 1998-05-27 1998-05-27 Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.
PCT/ES1999/000154 WO1999061030A1 (es) 1998-05-27 1999-05-26 USO DE DERIVADOS DEL ACIDO 2-HIDROXI-4-TRIFLUOROMETILBENZOICO COMO INHIBIDORES DE LA ACTIVACION DEL FACTOR DE TRANSCRIPCION NUCLEAR NF-λB

Publications (2)

Publication Number Publication Date
JP2002516283A true JP2002516283A (ja) 2002-06-04
JP2002516283A5 JP2002516283A5 (https=) 2006-07-27

Family

ID=8304002

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000550490A Pending JP2002516283A (ja) 1998-05-27 1999-05-26 核転写因子ＮＦ−κＢの活性化の阻害剤としての２−ヒドロキシ−４−トリフルオロメチル安息香酸誘導体の使用

Country Status (14)

Country Link
US (2) US6414025B1 (https=)
EP (2) EP1082962B1 (https=)
JP (1) JP2002516283A (https=)
KR (2) KR100762156B1 (https=)
AT (1) ATE245987T1 (https=)
AU (1) AU3828699A (https=)
BR (1) BR9911598A (https=)
CA (1) CA2332863A1 (https=)
DE (1) DE69910019T2 (https=)
DK (1) DK1082962T3 (https=)
ES (2) ES2136581B1 (https=)
NO (1) NO20005981L (https=)
PT (1) PT1082962E (https=)
WO (1) WO1999061030A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019048837A (ja) * 2009-03-18 2019-03-28 レスバーロジックス コーポレイション 新規抗炎症剤
JP2019531356A (ja) * 2016-10-14 2019-10-31 アンスティテュ パスツール デ モンテビデオＩｎｓｔｉｔｕｔ Ｐａｓｔｅｕｒ Ｄｅ Ｍｏｎｔｅｖｉｄｅｏ 多能性抗炎症及び代謝調節剤を用いた炎症関連症状の治療方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2154242B1 (es) * 1999-09-03 2001-10-16 Uriach & Cia Sa J Nuevos sistemas polimericos biocompatibles portadores de triflusal o htb.
US20040101488A1 (en) * 2000-03-24 2004-05-27 Balaram Ghosh Method for the prevention of septic shock lethality using curcumin
ES2190373B1 (es) * 2001-12-07 2004-10-16 J. URIACH & CIA, S.A. Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero.
CA2497977A1 (en) 2002-09-20 2004-04-01 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
JP5780521B2 (ja) 2008-05-28 2015-09-16 リベラジェン・バイオファーマ・インコーポレイテッドＲｅｖｅｒａＧｅｎ ＢｉｏＰｈａｒｍａ，Ｉｎｃ． 疾患を治療するための、ＮＦ−κＢの非ホルモン性ステロイド調節因子
WO2011127048A2 (en) 2010-04-05 2011-10-13 Validus Biopharma NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE
CN103665012B (zh) * 2013-12-06 2016-06-22 辽宁师范大学 新型三氟柳无机药物化合物及合成方法
WO2017004205A1 (en) 2015-06-29 2017-01-05 Reveragen Biopharma, Inc. NON-HORMONAL STEROID MODULATORS OF NF-κB FOR TREATMENT OF DISEASE
US20180016314A1 (en) * 2016-07-12 2018-01-18 Children's Hospital Medical Center Treatment of disease via transcription factor modulation
KR101975603B1 (ko) 2018-09-14 2019-08-28 이영문 조력 발전장치
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52156831A (en) * 1976-06-10 1977-12-27 Uriach & Cia Sa J Production of 44 trifluoromethyl benzoic acid derivatives and pharmaceutical composition containing same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1276071B1 (it) * 1995-10-31 1997-10-24 Nicox Ltd Compositi ad attivita' anti-infiammatoria

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52156831A (en) * 1976-06-10 1977-12-27 Uriach & Cia Sa J Production of 44 trifluoromethyl benzoic acid derivatives and pharmaceutical composition containing same

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019048837A (ja) * 2009-03-18 2019-03-28 レスバーロジックス コーポレイション 新規抗炎症剤
US10882828B2 (en) 2009-03-18 2021-01-05 Resverlogix Corp. Anti-inflammatory agents
US11407719B2 (en) 2009-03-18 2022-08-09 Resverlogix Corp. Anti-inflammatory agents
JP2019531356A (ja) * 2016-10-14 2019-10-31 アンスティテュ パスツール デ モンテビデオＩｎｓｔｉｔｕｔ Ｐａｓｔｅｕｒ Ｄｅ Ｍｏｎｔｅｖｉｄｅｏ 多能性抗炎症及び代謝調節剤を用いた炎症関連症状の治療方法

Also Published As

Publication number Publication date
DE69910019D1 (de) 2003-09-04
NO20005981D0 (no) 2000-11-27
EP1362592A1 (en) 2003-11-19
ATE245987T1 (de) 2003-08-15
CA2332863A1 (en) 1999-12-02
WO1999061030A1 (es) 1999-12-02
EP1082962B1 (en) 2003-07-30
US20030032630A1 (en) 2003-02-13
US6610745B2 (en) 2003-08-26
DK1082962T3 (da) 2003-11-24
NO20005981L (no) 2000-12-12
PT1082962E (pt) 2003-11-28
KR20010052404A (ko) 2001-06-25
ES2204129T3 (es) 2004-04-16
BR9911598A (pt) 2001-02-13
KR20070006943A (ko) 2007-01-11
KR100762156B1 (ko) 2007-10-04
EP1082962A1 (en) 2001-03-14
ES2136581A1 (es) 1999-11-16
DE69910019T2 (de) 2004-05-06
ES2136581B1 (es) 2000-09-16
AU3828699A (en) 1999-12-13
KR100713601B1 (ko) 2007-05-02
US6414025B1 (en) 2002-07-02

Similar Documents

Publication Publication Date Title
JP2002516283A (ja) 核転写因子ＮＦ−κＢの活性化の阻害剤としての２−ヒドロキシ−４−トリフルオロメチル安息香酸誘導体の使用
WO2021135654A1 (zh) 双硫仑在制备防治nlrp3炎症小体相关疾病的药物中的应用
AU2021260040A1 (en) Vidofludimus for use in the treatment or prevention of viral diseases
CN117503932B (zh) Jun抑制剂在制备用于治疗射血分数保留的心衰的药物中的用途
JPH085780B2 (ja) 変形性関節症治療剤
CN114288288A (zh) 一种gsdmd抑制剂及在制备神经免疫疾病、炎症感染疾病防治药物中的应用
CN111902531A (zh) 用于改善、预防或治疗类风湿性关节炎的长双歧杆菌rapo菌株及包含其的组合物
Yang et al. BRD4 expression in patients with essential hypertension and its effect on blood pressure in spontaneously hypertensive rats
WO2003039557A1 (en) Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection
EP2120919B1 (en) New combination for use in the treatment of inflammatory disorders
KR102521352B1 (ko) 조성물
JP6081025B2 (ja) モノアセチルジアシルグリセロール化合物を有効成分として含有する喘息の予防または治療用組成物
WO2012020821A1 (ja) 非アルコール性脂肪肝炎の予防または治療剤
JPWO2008111295A1 (ja) 全身性エリテマトーデスの予防及び／又は治療剤
JP2001500143A (ja) ウイルス性疾患の治療のための薬剤学的組成物
EP0978277A1 (en) Antirheumatic agents
JP2009533414A (ja) 動脈症治療薬の調製のためのアミナフトンの使用
KR101213948B1 (ko) 잔가시모자반으로부터 분리한 활성물질을 이용한 항염증성 조성물
US20040122059A1 (en) PPAR-gamma ligands in the treatment of asthma and allergies
JP2025525568A (ja) 自己免疫疾患の治療のための医薬の製造におけるナフトキンリン酸塩の使用
CN112245422B (zh) 乙酰缬草素的新应用
US6509377B1 (en) Use of a 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factor NF-κB
KR20120056243A (ko) 피페린 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 염증성 질환 예방 및 치료용 조성물
CN103547262A (zh) 甘草查耳酮a的新用途
CN111166756B (zh) 20（S）-人参皂苷-Rg3在逆转胶质瘤细胞对化疗药物的耐药性中的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060525

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20060525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060525

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080710

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20080904

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20081002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100716